Akso Health Group

What Akso Health Group does

Akso Health Group (NASDAQ: AHG) is a Cayman Islands-incorporated, Beijing-headquartered healthcare company that has pivoted from its origins as Hexindai Inc. (micro-lending) and Xiaobai Maimai Inc. (social e-commerce) into an integrated online-offline healthcare services platform. The company serves cancer patients, Chinese consumers seeking remote medical care, and medical institutions procuring medical supplies, operating across four core lines: a Health Mall e-commerce platform for medical devices and consumables, a Telemedicine Platform with six modules (Internet Hospital, Nursing, Appointment Registration, Public Health Emergency, Telemedicine Collaboration, and Intelligent Convenience Services), an Offline Tumor Treatment Platform, and a Vaccine R&D program. Its U.S. oncology expansion is run through wholly-owned We Health Limited in New York, with plans for 100 radiation oncology centers on the U.S. east coast.

The company's technology stack centers on an AI layer built around DeepSeek's multimodal large-scale models, integrated in February 2025 to power an AI diagnosis system that fuses patient text descriptions, medical imaging, and laboratory test results, plus an AI medical assistant that helps doctors retrieve records and recommend treatment plans. Telemedicine infrastructure supports online consultation in text, voice, and video, electronic prescriptions, medicine delivery, and home-based nursing. In April 2026 the company launched a proprietary Brain-Computer Interface R&D program targeting ultra-high-resolution neural sensing, real-time AI neural decoding, and next-generation interface design, with patent applications pending but no clinical trials, regulatory submissions, or revenue yet.

Akso Health's business model is predominantly direct-to-consumer via its telemedicine and e-commerce platforms, complemented by enterprise channels for medical device sales to healthcare providers and B2B2C delivery of radiotherapy oncology services. FY2022 net revenues were approximately $6.3 million, of which medical device sales accounted for roughly $6 million (about 95%), with online marketplace services contributing about $96,332 and legacy interest income about $215,393. Online medical consultations are delivered through Tianjin Deyihui Internet Hospital and Tianjin Deyihui Clinic, in which the company acquired equity interests in March 2024. Cash and cash equivalents stood at $21.9 million as of March 31, 2022, supplemented by a $10.02 million private placement completed in September 2021. Pricing is not publicly disclosed and is negotiated individually based on service requirements.

Name

Akso Health Group

Legal name

Akso Health Group

Website

https://ahgtop.com

Company type

Public

Founded year

2016

Operating status

Operating

Short description

Akso Health Group (NASDAQ: AHG) is a Cayman-incorporated, Beijing-headquartered healthcare company operating a telemedicine platform, medical-device health mall, and planned U.S. radiation oncology centers, serving cancer patients, Chinese healthcare consumers, and medical institutions.

Ownership category

akta.pro rank

Product category

Telemedicine and Healthcare Services

NAICS

Scientific Research and Development Services (5417)

SIC

Services-Health Services (8000), Surgical & Medical Instruments & Apparatus (3841)

akta.pro primary industry

Patient Engagement, Education & Messaging Platforms (portal/CRM integrated) (HLALABAJ)

akta.pro secondary industry

Remote Diagnostics & Point-of-Care (Connected Testing, Home Lab Devices) (HLACAPAK)

Keywords

• Telemedicine services
• Healthcare e-commerce
• Cancer treatment services
• Vaccine research development
• Medical device sales

Headquarters

HQ city

Chaoyang

HQ country

Taiwan

HQ region

Asia

Offices4 records

Markets served

GTM type

B2C

Offering type

Services

Cost components

Personnel, Operations, Technology or R&D, Marketing or Sales, Supply Chain, Infrastructure

Revenue model

1. Medical Device Sales: Sales of medical devices in China and the United States. Revenue from sale of medical devices was approximately $6 million in fiscal year 2022.
2. Online Marketplace Services: Commission revenue from social e-commerce platform serving the domestic Chinese market. Revenue from online marketplace services was approximately $96,332 in fiscal year 2022.
3. Radiotherapy Oncology Services: Planned radiotherapy oncology center operations in the United States. The company plans to open 100 radiation oncology centers on the east coast serving cancer patients.
4. Telemedicine Services: Online medical consultations for initial diagnosis, follow-up consultations, and management of chronic diseases through Tianjin Deyihui Internet Hospital and Tianjin Deyihui Clinic.
5. Interest Income: Historical interest income from micro-lending business. The company has ceased issuing new loans since May 2019 and exited the micro-lending business in October 2019. Interest income was approximately $215,393 in fiscal year 2022.

Go-to-market motion2 records

Distribution channels4 records

Marketing channels2 records

Core offering

Akso Health Group operates an integrated online-offline healthcare services platform serving consumers and medical institutions in China and the United States. The company's offerings include a Health Mall e-commerce marketplace for medical products, a Telemedicine Platform for online consultations and digital health services, Offline Tumor Treatment services for cancer care including planned radiation oncology centers, and Vaccine R&D services. The company also develops proprietary AI-powered diagnostic tools using DeepSeek technology and a Brain-Computer Interface (BCI) R&D program.

Product overview

Akso Health Group operates an integrated multi-platform health services ecosystem combining online and offline channels. The core portfolio consists of four main offerings: the Health Mall (medical and health e-commerce marketplace), the Telemedicine Platform (digital health services with six integrated modules), the Offline Tumor Treatment Platform (cancer care and radiation oncology services), and Vaccine R&D Services. The telemedicine platform is built around the Intelligent Internet Hospital Platform, Internet Nursing Service Platform, Intelligent Appointment Registration Platform, Public Health Emergency Service Platform, Telemedicine Collaboration Platform, and Intelligent and Convenient Service Platform. AI-powered features including the AI-Powered Diagnosis System and AI-Powered Medical Assistant enhance service delivery using DeepSeek technology. The company is expanding into Brain-Computer Interface technology R&D. The company formerly operated a social e-commerce business in China and has pivoted toward healthcare services including medical device sales, radiotherapy oncology center operations in the U.S., and online medical consultations through acquired internet hospital entities.

Differentiator

Problem solved

Functional benefit

Brands

• Intelligent Internet Hospital Platform: Online consultation platform providing image, text, voice, video consultation, online outpatient clinic, and electronic prescription services
• Internet Nursing Service Platform
• Intelligent Appointment Registration Platform
• Public Health Emergency Service Platform
• Telemedicine Collaboration Platform
• AHG Tumor Treatment Platform
• Vaccine R&D Center

Products and services

• Health Mall Medical and health e-commerce marketplace offering clinical laboratory equipment, diagnostic reagents, medical imaging equipment, surgical equipment, dental equipment, rehabilitation products, scientific instruments, and personal health products for medical institutions, laboratories, and consumers in China.
• Telemedicine Platform Digital health platform providing remote diagnosis and treatment services including online consultation, electronic prescriptions, medication delivery, home-based nursing services, appointment registration, public health monitoring, and telemedicine collaboration for healthcare providers and patients.
• Offline Tumor Treatment Platform Cancer treatment services platform offering DNA testing, report interpretation, offline tumor specialist diagnosis, prescribing and medication delivery, commercial insurance payment processing, periodic precision treatment, and post-consultation patient welfare. Includes planned radiation oncology centers on the U.S. east coast.
• Vaccine R&D Services Vaccine research and development services including tumor antigen vaccine development, infectious disease vaccine development, and edible vaccine development. The company plans to establish 2 vaccine research centers for AIDS and COVID-19.
• Brain-Computer Interface (BCI) Technology Proprietary next-generation Brain-Computer Interface technology under development targeting neurotechnology applications. Focus areas include ultra-high-resolution neural sensing, real-time AI neural decoding, and next-generation interface design for neuroscience, advanced therapeutics, and human-machine interaction.

Quantifiable outcome

• 8,750 average monthly mobile active users as of September 2021
• +2 more outcomes

Named customers1 record

Segments3 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability7 records

Feature4 records

Partnerships

One partnership is on record.

• Research InstitutecoreStrategic or Co-development Partner · 3 February 2026Strategic cooperation framework agreement where Research Institute provides exclusive cancer diagnosis and treatment technologies, reagent and consumable supply system, professional laboratory testing capabilities, and an exclusive team of cancer diagnosis and treatment experts. The partnership aims to build a closed-loop model of global resource connection plus local technology landing plus full-cycle patient service.

Scale indicators11 records

Recent moves9 records

Expansion highlights6 records

Broad incumbents

• Accolade: Healthcare navigation and virtual care platform providing personalized advocacy, telemedicine access, and chronic condition support. Comparable as a broader incumbent in the integrated virtual care and patient engagement space where Akso's Intelligent Internet Hospital Platform competes.
• Teladoc Health: Largest U.S. telehealth operator providing virtual care, chronic condition management, and integrated health services. While geographically separate from Akso's Chinese core, comparable as a benchmark telemedicine platform with similar virtual consultation and chronic disease management offerings.

Emerging players

• Doximity: Digital platform for medical professionals offering telehealth workflows, patient communication, and clinical tools. Comparable to Akso's Telemedicine Collaboration Platform module that enables remote consultation and provider-to-provider communication.
• Lunit: AI medical imaging company developing deep learning-based diagnostic solutions for cancer detection. Directly comparable to Akso's DeepSeek-powered AI diagnostic system that integrates medical imaging with text and lab data for cancer diagnosis and treatment recommendations.
• Hims & Hers Health: D2C telehealth platform combining online consultation with prescription drug delivery and consumer health products. Comparable to Akso's telemedicine-plus-direct-fulfillment model (e-prescription plus medicine delivery) and D2C go-to-market motion.

Direct peers

• JD Health International: Major Chinese healthcare e-commerce and online consultation platform combining retail pharmacy with telehealth services. Closely comparable to Akso's Health Mall e-commerce marketplace plus telemedicine offering, targeting similar Chinese consumer healthcare needs.
• Ping An Healthcare and Technology: Chinese integrated online healthcare platform offering telemedicine consultations, e-prescriptions, and chronic disease management. Directly comparable to Akso's Intelligent Internet Hospital Platform and Tianjin Deyihui online consultation business in both product offering and target customer base.
• Amwell: U.S. enterprise-focused telemedicine platform enabling health systems to deliver virtual care, including behavioral health and chronic care programs. Closely comparable to Akso's telemedicine infrastructure serving healthcare providers and patients via online consultations.
• Alibaba Health Information Technology: Hong Kong-listed Chinese healthcare platform operating pharmaceutical e-commerce, online consultation, and medical AI services through its parent ecosystem. Comparable to Akso across both the Health Mall product distribution and Internet Hospital telemedicine businesses.

Others

• Akeso (Akeso, Inc.): Hong Kong-listed Chinese biopharmaceutical company developing oncology and immunology therapeutics. Adjacent/peer-like as both companies are Chinese healthcare firms targeting oncology through complementary mechanisms — Akso via radiotherapy centers and Akeso via antibody drug development.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat3 records

Key risks1 record

Key highlights6 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Profiles6 records

Subsidiaries3 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Akso Health Group